Alba Jimenez-Masip

Alba Jimenez-Masip


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JRJesús Rivera-Esteban
Jesús Rivera-Esteban
AJAlba Jimenez-Masip
Alba Jimenez-Masip
SMSergio Muñoz-Martínez
Sergio Muñoz-Martínez
SASalvador Augustin
Salvador Augustin
RGRafael A. Guerrero
Rafael A. Guerrero
OCon behalf of the PRISONAFLD Study Group Collaborators
on behalf of the PRISONAFLD Study Group Collaborators
Background and Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of this syndrome. We aimed to investigate the prevalence and risk factors of MASLD and MASLD-associated liver fibrosis in the penitentiary population in Catalonia, Spain. Method: A cross-sectional observational study involving eight penitentiary centers. Participants had at least one metabolic disorder and were at a closed-regimen penitentiary. Individuals with concomitant liver diseases and/or alcohol risk consumption were excluded. Significant fibrosis and MASLD were defined as liver stiffness ≥8 kPa and a controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, metabolic inmates with VCTE were analyzed. Logistic regression analysis was performed to identify predictors of MASLD and MASLD-associated significant fibrosis. Results: Out of the 4338 inmates studied, 1290 (29.7%) had metabolic disorders, and 646 (14.9%) underwent VCTE. The mean age was 48.0 years (SD 12.1), and 89.5% were male. MASLD prevalence was 33.9%. Significant fibrosis and MASLD-associated significant fibrosis were found in 16.4% and 9.4% of inmates, respectively. In the multivariate analysis, T2D, waist circumference, MetS, and higher ALT values were identified as independent risk factors for MASLD and MASLD-associated significant fibrosis amongst the prison population. Conclusions: Metabolic disorders including MASLD are highly prevalent among inmates. The prevalence of significant fibrosis seems notably higher than that of the general population, underscoring the need for targeted screening programs and therapeutic interventions in the incarcerated population.

11 March 2026 in Hepatology Communications
Verified
Journal Article
Open access
AJAlba Jimenez-Masip
Alba Jimenez-Masip
TBTeresa Broquetas
Teresa Broquetas
SMSergio Muñoz-Martínez
Sergio Muñoz-Martínez
ISIsabel Serra-Matamala
Isabel Serra-Matamala
DRDiego Rojo
Diego Rojo
Juan M. PericàsJuan M. Pericàs
Juan M. Pericàs
Background: Whether patients with metabolic dysfunction–associated steatotic liver disease (MASLD) cirrhosis can achieve recompensation is still a subject of debate. This study aimed to evaluate the incidence and factors associated with recompensation in patients with decompensated MASLD cirrhosis. Methods: Cohort study across 4 university hospitals in Barcelona (Spain), enrolling individuals with MASLD cirrhosis at their initial decompensating event. Liver recompensation (Baveno VII) was defined as the absence of clinical decompensation after discontinuation of specific treatment, along with sustained improvement in liver function. Competing-risk regression models were used to identify predictors of recompensation. Results: Among 124 patients [mean age: 69 years (IQR 62–73), 53% males], 59% had obesity, 74% type 2 diabetes, 66% arterial hypertension, and 47% dyslipidemia. Most patients were Child–Pugh B (61%) with a median MELD-Na score of 11 (IQR 10–16). After a median follow-up of 2.1 years (IQR 0.97–4.53), the 2-year cumulative incidence of recompensation was 24%. Factors associated with recompensation included MELD-Na (aSHR 0.891 [95% CI 0.833–0.953]; p =0.001), albumin (aSHR 1.894 [95% CI 1.008–3.297]; p =0.024, ascites (aSHR 0.475, [95% CI 0.268–0.841]; p =0.011), and multiple decompensation (aSHR 0.151 [94% CI 0.033–0.698]; p =0.015) as a first decompensation event. Although a substantial proportion of patients initially achieved recompensation, this was frequently transient, and its apparent survival benefit did not persist after adjustment for liver function and accounting for time-dependence. Conclusions: Liver recompensation in MASLD cirrhosis occurs in 24% of patients within 2 years after first decompensation and is mainly dependent on basal liver function. However, frequent further decompensation limits its prognostic impact on survival.

9 March 2022 in Gastroenterología y Hepatología
Verified
Journal Article
Closed access
LALuis Gerardo Alcala-Gonzalez
Luis Gerardo Alcala-Gonzalez
AJAlba Jimenez-Masip
Alba Jimenez-Masip
LRLucia Relea-Pérez
Lucia Relea-Pérez
CBClaudia Barber-Caselles
Claudia Barber-Caselles
EBElizabeth Barba-Orozco
Elizabeth Barba-Orozco

1 October 2025 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
AMAndrew Makary
Andrew Makary
DRDiego Rojo
Diego Rojo
LPLaura Pagès
Laura Pagès
CSClara Sabiote
Clara Sabiote
AJAlba Jimenez-Masip
Alba Jimenez-Masip
Juan M. PericàsJuan M. Pericàs
Juan M. Pericàs
Opportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes

12 June 2026 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
BHBenedikt Silvester Hofer
Benedikt Silvester Hofer
SSSarah Shalaby
Sarah Shalaby
WKWilhelmus Kwanten
Wilhelmus Kwanten
DSDario Saltini
Dario Saltini
LTLuis Téllez
Luis Téllez
GSGeorg Semmler
Georg Semmler
Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated liver disease (MASLD), alcohol-related liver disease (ALD), and a mixed type (MetALD). We investigated the course of compensated advanced chronic liver disease (cACLD) across SLD subtypes, the impact of clinically significant portal hypertension (CSPH), and the role of non-invasive tests (NITs). This study included SLD patients with cACLD from 17 centers undergoing hepatic venous pressure gradient (HVPG) and NIT assessment through December 2023. Primary outcomes were first hepatic decompensation and liver-related mortality. Among 696 patients (ALD 22%, MetALD 20%, MASLD 58%), 94% had Child-Pugh A, and 60% had CSPH. Over a median follow-up of 3.8 years, 170 patients decompensated and 137 died (58% liver-related). The three-year cumulative decompensation incidence was highest in ALD (26%), followed by MetALD (21%) and MASLD (15%), yet differences were no longer significant after adjusting for age, sex, MELD, albumin, and HVPG. Similarly, liver-related mortality did not differ by SLD subtype in adjusted models. CSPH independently predicted decompensation across all subtypes. The ANTICIPATE-NASH model showed high and comparable diagnostic accuracy for CSPH across ALD, MetALD, and MASLD (AUROC 0.831-0.894). An ANTICIPATE-NASH probability ≥60% for ruling-in CSPH outperformed the original ANTICIPATE model in all subtypes and independently predicted decompensation with similar effect sizes (aSHR 2.57-2.71). Higher crude decompensation rates in ALD and MetALD reflect more severe liver disease at presentation, yet outcomes are comparable across the SLD spectrum after accounting for disease severity. ANTICIPATE-NASH accurately identifies CSPH across SLD subtypes, and both invasive and non-invasive measures of portal hypertension predict decompensation and liver-related death.

19 June 2026 in Hepatology Communications
Verified
Journal Article
Open access
AJAlba Jimenez-Masip
Alba Jimenez-Masip
Juan M. PericàsJuan M. Pericàs
Juan M. Pericàs